washingtonpost.com
Your Child's First Statin -- but
Does He Need It?
Tuesday, May 7, 2002; Page HE03
The recent Food and Drug Administration (FDA) approval of the first statin drug for use by children may improve treatment of high blood cholesterol for some, but it's also raising concern about inappropriate use of a powerful drug in kids.
The American Academy of Pediatrics (AAP) worries that the FDA's February approval of Merck's Mevacor (lovastatin) -- for children with a disorder that gives them very high blood cholesterol -- could fuel more statin use when there is still little long-term safety and efficacy data in children, said John Moore, a pediatric cardiologist at Philadelphia's M.C. Hahnemann Medical Center and chairman of the AAP's cardiology section. There's also no consensus on how best to treat high cholesterol in youngsters, he said. The academy is expected to write new guidelines in late July.
The most recent National Cholesterol Education Program guidelines say drug therapy should be considered in adults when LDL (or "bad") cholesterol rises above 190, or above 160 when there are two or more risk factors for cardiovascular disease. The same rules are usually followed in children, said Stephen Daniels, a pediatric cardiologist at the Cincinnati Children's Hospital Medical Center. There are no good figures on how many children have dangerous LDL levels, but the American Heart Association estimates that 10 percent of children aged 12 to 19 have high total cholesterol levels -- above 200.
Daniels predicted most pediatricians will be circumspect in prescribing Mevacor for children. "My guess is that there's not going to be an explosion in usage," he said. But others, like Moore, are less certain.
Mevacor was approved specifically for children aged 10 to 17 who have heterozygous familial hypercholesterolemia (HFH), an inherited condition that affects one in 500 Americans and puts them at very high risk for early heart disease and death. But "off-label" use of statins for uses beyond those for which they are specifically approved is common. Many pediatric cardiologists use statins already to lower cholesterol in children, and it's possible that the approval of Mevacor for children will open the door to wider pediatric use for children with milder cholesterol problems.
In Merck's two studies of boys and girls with HFH, Mevacor cut cholesterol by 25 to 30 percent -- "on par with what we see in adults," said David Orloff, director of FDA's division of metabolic and endocrine drugs. But because the trials were short-term -- boys were studied for one year, girls for six months -- it is not known if Mevacor will slow the progression of heart disease in children or have unforeseen side effects.
Pete Kwiterovich, director of the University Lipid Clinic at Johns Hopkins University Medical Center and lead investigator in both trials, said the drug showed no evidence of two common statin effects -- liver and muscle damage. Mevacor also did not appear to affect growth or sexual development during the period of study -- both particular concerns, since cholesterol plays a key role in growth and sex hormone synthesis.
Mevacor for children is the same formulation as the adult product but in a lower dose -- up to 40 milligrams a day, half that used in adults. Since the drug lost its patent protection last year, cheaper generics have become available. But the approval for use in children permits Merck to market the brand-name drug for that use, something the other statins, including the generics, may not do.
© 2002 The Washington Post Company
|
I promise to answer your message -- click here to send me a personal message
|
SUBSCRIBE: The Wednesday Letter is a free electronic monthly newsletter written and published by Karl Loren. You can view more than 50 back issues of this publication by clicking here. The Wednesday Letter subscription list is maintained on a secure server, no name is ever given or sold to anyone, and it is never used except for this Newsletter. It is automatically published on the Tuesday night just before the first Wednesday of every month. You can subscribe to this free monthly electronic letter by entering your eMail address and name below. You will then automatically receive a request for confirmation, sent to whatever address you have entered. If you do NOT receive this confirmation request, then you will not be subscribed. There may have been an error with your address and you should resubmit. The letter is never sent twice to the same address -- so you do not have to worry about a duplicate subscription. When you receive this confirmation request you must reply to it, or your subscription will not become active. No one can subscribe your name, and address, without you being notified, and if you get an unwanted notice of subscription you only need to DO NOTHING and the subscription will NOT be active.
REMOVAL: You can remove yourself from the subscription list in several different ways. Click here to read about this entire newsletter system. Every edition of The Wednesday Letter is delivered to your address with YOUR name and address in view on the letter, with a link that allows you to remove THAT name from the subscription list. If you try to send this removal message from an address different from the one you used to send in your original confirmation, then you will get a warning notice first, sent to the subscription address, asking you to confirm that you want to be removed from the list -- by replying to THAT request for confirmation, you will then be automatically removed. Thus, no one else can unsubscribe you, from some other computer, without your knowledge. But, if you send in the unsubscribe notice from the same machine used to receive the Letter, then the removal from the subscription list is automatic.
Personal Message: When you send a personal message to Karl Loren, you will receive a personal reply as per his instructions. Karl pledges that every personal message will get a personal answer. When you provide your mail address, we will send you free information including our free catalog and a cassette tape lecture by Karl Loren about heart disease, no charge, by mail, even if outside the US. You can select particular information you would like to receive, along with the free cassette tape and catalog.
You can reach Vibrant Life in many ways, including by mail to Vibrant Life, 2808 N. Naomi St., Burbank, CA 91504. Within the US and Canada, use the toll free number: (800) 523-4521, the local number: (818) 558-1799, the FAX: (818) 558-7299, eMail to kimberly@oralchelation.com or any one of the hundreds of message forms throughout the 50 web sites. Vibrant Life normally ships the same day we get an order. There are message forms on each of the 100,000+ pages on this and other sites where you can communicate with Vibrant Life. Check out our companion site, at: http://www.oralchelation.net where Karl's 2000 page book is published. Karl Loren is the author and webmaster for this BOOK, as well as for another web site about ORAL CHELATION. His personal philosophical articles are at PHILOSOPHY.
Copyright © May 20, 2008 6:24 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED. Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions: One, that some form of copyright notice is included in every copy distributed or copied, showing the copyright belonging to Vibrant Life, Burbank, CA, at www.oralchelation.com . The second condition is that the material is not to be used for any purpose contrary to the purposes and objectives of this site. This permission does not extend to materials on this site which are copyrighted by others.
